Imidazole Carbamates as a Promising Alternative for Treating Trichomoniasis: In Vitro Effects on the Growth and Gene Expression of Trichomonas vaginalis

Víctor Martínez-Rosas,Gabriel Navarrete-Vázquez,Daniel Ortega-Cuellar,Roberto Arreguin-Espinosa,Verónica Pérez de la Cruz,Ernesto Calderón-Jaimes,Sergio Enríquez-Flores,Carlos Wong-Baeza,Isabel Baeza-Ramírez,Laura Morales-Luna,Montserrat Vázquez-Bautista,Miriam Abigail Rojas-Alarcón,Beatriz Hernández-Ochoa,Saúl Gómez-Manzo
DOI: https://doi.org/10.3390/molecules29112585
IF: 4.6
2024-06-01
Molecules
Abstract:Metronidazole (MTZ) is the most common drug used against Trichomonas vaginalis (T. vaginalis) infections; however, treatment failures and high rates of recurrence of trichomoniasis have been reported, suggesting the presence of resistance in T. vaginalis to MTZ. Therefore, research into new therapeutic options against T. vaginalis infections has become increasingly urgent. This study investigated the trichomonacidal activity of a series of five imidazole carbamate compounds (AGR-1, AGR-2, AGR-3, AGR-4, and AGR-5) through in vitro susceptibility assays to determine the IC50 value of each compound. All five compounds demonstrated potent trichomonacidal activity, with IC50 values in the nanomolar range and AGR-2 being the most potent (IC50 400 nM). To gain insight into molecular events related to AGR-induced cell death in T. vaginalis, we analyzed the expression profiles of some metabolic genes in the trophozoites exposed to AGR compounds and MTZ. It was found that both AGR and MTZ compounds reduced the expression of the glycolytic genes (CK, PFK, TPI, and ENOL) and genes involved in metabolism (G6PD, TKT, TALDO, NADHOX, ACT, and TUB), suggesting that disturbing these key metabolic genes alters the survival of the T. vaginalis parasite and that they probably share a similar mechanism of action. Additionally, the compounds showed low cytotoxicity in the Caco-2 and HT29 cell lines, and the results of the ADMET analysis indicated that these compounds have pharmacokinetic properties similar to those of MTZ. The findings offer significant insights that can serve as a basis for future in vivo studies of the compounds as a potential new treatment against T. vaginalis.
chemistry, multidisciplinary,biochemistry & molecular biology
What problem does this paper attempt to address?
### Problems the Paper Attempts to Solve This paper aims to address the treatment issues of **Trichomoniasis**, a sexually transmitted infection caused by **Trichomonas vaginalis**. Currently, the main drug used to treat Trichomoniasis is **Metronidazole (MTZ)**, but this drug has several issues: 1. **Treatment failure and high recurrence rate**: There are reports of treatment failure and high recurrence rates when using Metronidazole to treat Trichomoniasis, which may be due to the development of drug resistance by Trichomonas vaginalis. 2. **Side effects**: The use of Metronidazole can cause a range of side effects, such as vomiting, diarrhea, abdominal pain, dizziness, and in severe cases, encephalopathy. These side effects may lead to patients discontinuing treatment. 3. **Drug resistance**: Laboratory studies have found that Trichomonas vaginalis can develop resistance to Metronidazole by reducing the expression of certain genes and proteins. Given these issues, researching new treatment options has become very urgent. Therefore, this paper investigates a new class of compounds—**Imidazole Carbamates**, specifically five compounds (AGR-1, AGR-2, AGR-3, AGR-4, and AGR-5), to evaluate their effects on the growth and gene expression of Trichomonas vaginalis in vitro, and their potential as new treatment drugs. ### Main Research Content 1. **Screening compounds with anti-Trichomonas activity**: Screening compounds through in vitro experiments that can inhibit the viability of Trichomonas vaginalis. 2. **Determining the half-maximal inhibitory concentration (IC50) of the compounds**: Determining the effective concentration of each compound by treating Trichomonas vaginalis with different concentrations of the compounds. 3. **Evaluating the cytotoxicity of the compounds**: Testing the cytotoxicity of these compounds on human cell lines (such as Caco-2 and HT29 cells) to ensure their safety. 4. **Analyzing changes in gene expression**: Studying the changes in the expression of metabolism-related genes in Trichomonas vaginalis after treatment with these compounds to understand their mechanism of action. ### Results 1. **Anti-Trichomonas activity**: All five Imidazole Carbamate compounds showed significant anti-Trichomonas activity, with AGR-2 being the most effective, having an IC50 value of 400 nM. 2. **Low cytotoxicity**: These compounds exhibited low cytotoxicity in Caco-2 and HT29 cell lines, and had a high selectivity index (SI), indicating strong selective toxicity towards Trichomonas vaginalis. 3. **Changes in gene expression**: Both these compounds and Metronidazole were able to reduce the expression of genes related to glycolysis and metabolism in Trichomonas vaginalis, suggesting they may act through similar mechanisms. ### Significance This study provides important foundational data for the development of new anti-Trichomonas drugs. These new compounds may become effective alternatives for the future treatment of Trichomoniasis.